Skip to content
2000
Volume 9, Issue 4
  • ISSN: 1573-403X
  • E-ISSN: 1875-6557

Abstract

Transcatheter aortic valve implantation (TAVI) is evolving rapidly as a therapeutic option in patients deemed to be at high risk for surgical aortic valve replacement. Early outcome and survival of controlled feasibility trials and single- center experience with TAVI have been previously reported. Valve performance and hemodynamics seem to improve significantly after TAVI. Long-term outcome up to 3 years have been demonstrated in recent studies. Admittedly, the results are encouraging with a survival rate at 2 and 3 years ranging from 62 to 74% and from 56 to 61% respectively. The improvement in hemodynamical and clinical status sustained beyond the 3 years follows up. However, paravalvular leakage after TAVI remains an important issue in this rapidely evolving field.

Loading

Article metrics loading...

/content/journals/ccr/10.2174/1573403X09666131202124227
2013-11-01
2025-09-04
Loading full text...

Full text loading...

/content/journals/ccr/10.2174/1573403X09666131202124227
Loading

  • Article Type:
    Research Article
Keyword(s): aortic stenosis; Aortic valve; paravalvular leakage; SAVR; TAVI
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test